Klassen T P
Research Institute, Children's Hospital of Eastern Ontario, Ottawa, Canada.
Pediatr Clin North Am. 1997 Feb;44(1):249-61. doi: 10.1016/s0031-3955(05)70472-7.
Progress has been made in the treatment for patients with croup and bronchiolitis in the past decade. By intervening with pharmacologic agents, a better outcome has been documented in children with these diseases. A lower probability of hospital admission means that fewer health care dollars need to be expended in this area. The present state of evidence substantiates the following. Bronchiolitis . Nebulized albuterol causes significant short-term improvement in clinical scores in bronchiolitic children, but there is no evidence that it reduces admission rates or decreases length of hospitalization. . Nebulized epinephrine results in significant improvement in clinical scores and airway resistance in children hospitalized with bronchiolitis and in the emergency department causes acute improvement in oxygenation, decreases length of time in the emergency department and admission rate to hospital. . There is no evidence to support the use of dexamethasone or other glucocorticosteroids for infants hospitalized with bronchiolitis. Croup . Nebulized budesonide or oral dexamethasone results in acute clinical improvement in outpatients with mild to moderate croup, reducing the need for hospitalization. . A combination of nebulized budesonide and oral dexamethasone may provide the best clinical outcome, although further evidence is needed to substantiate this . The required dose of oral dexamethasone may range from 0.15 mg/kg to 0.6 mg/kg for best clinical outcome. . Use of racemic epinephrine or L-epinephrine in the emergency department, especially when used concomitantly with glucocorticoids, does not require automatic hospital admission; a 3-hour observation period in the emergency department may suffice. . Use of intramuscular dexamethasone is difficult to justify in patients with croup who are able to ingest oral medications. Future studies need to examine dosing of glucocorticoids for inpatients with croup. In addition, an important question remains as to whether very mild croup patients (those with no evidence of respiratory distress) might benefit from glucocorticoids administered in the physician's office or the emergency department.
在过去十年中,小儿喉炎和细支气管炎患者的治疗取得了进展。通过使用药物进行干预,已证明患有这些疾病的儿童能取得更好的治疗效果。住院概率降低意味着该领域所需的医疗费用减少。现有证据证实了以下几点。
雾化沙丁胺醇可使细支气管炎患儿的临床评分在短期内显著改善,但没有证据表明它能降低住院率或缩短住院时间。
雾化肾上腺素可使住院治疗的细支气管炎患儿的临床评分和气道阻力显著改善,在急诊科可使氧合情况急性改善,缩短在急诊科的时间并降低住院率。
没有证据支持对住院的细支气管炎婴儿使用地塞米松或其他糖皮质激素。
雾化布地奈德或口服地塞米松可使轻至中度小儿喉炎门诊患者的临床症状急性改善,减少住院需求。
雾化布地奈德和口服地塞米松联合使用可能会提供最佳临床效果,不过还需要进一步证据来证实这一点。
为获得最佳临床效果,口服地塞米松的所需剂量可能在0.15毫克/千克至0.6毫克/千克之间。
在急诊科使用消旋肾上腺素或L-肾上腺素,尤其是与糖皮质激素联合使用时,并不一定需要住院;在急诊科观察3小时可能就足够了。
对于能够口服药物的小儿喉炎患者,使用肌肉注射地塞米松很难说得过去。未来的研究需要探讨住院小儿喉炎患者糖皮质激素的给药剂量。此外,一个重要问题仍然存在,即非常轻度的小儿喉炎患者(那些没有呼吸窘迫迹象的患者)是否可能从在医生办公室或急诊科给予的糖皮质激素中获益。